This site is intended for healthcare professionals

FDA accepts BLA for tislelizumab to treat esophageal squamous cell carcinoma.

Read time: 1 mins
Last updated:14th Sep 2021
Published:14th Sep 2021
BeiGene, Ltd. has announced that the FDA accepted for review a Biologics License Application (BLA) for its anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy.
Condition: Oesophageal Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest